Published in J Neurosci on September 12, 2012
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology (2013) 1.61
Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci (2014) 1.25
A fatty gut feeling. Trends Endocrinol Metab (2013) 1.10
Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol (2013) 0.96
Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci (2014) 0.95
Advances in the discovery of N-acylethanolamine acid amidase inhibitors. Pharmacol Res (2014) 0.91
A lipid gate for the peripheral control of pain. J Neurosci (2014) 0.88
Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines? Front Cell Neurosci (2014) 0.85
Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells. J Pain Res (2013) 0.85
Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat (2014) 0.84
A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation. ACS Chem Biol (2015) 0.83
Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold. Int J Inflam (2013) 0.83
3-Aminoazetidin-2-one derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors suitable for systemic administration. ChemMedChem (2014) 0.82
Localization of peroxisome proliferator-activated receptor alpha (PPARα) and N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) in cells expressing the Ca(2+)-binding proteins calbindin, calretinin, and parvalbumin in the adult rat hippocampus. Front Neuroanat (2014) 0.82
Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. Neurobiol Dis (2013) 0.81
Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical. J Pain Res (2013) 0.81
Activity-Based Probe for N-Acylethanolamine Acid Amidase. ACS Chem Biol (2015) 0.80
Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. Int Med Case Rep J (2013) 0.79
An update on PPAR activation by cannabinoids. Br J Pharmacol (2016) 0.78
N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia. Pain (2012) 0.77
The endocannabinoid system - a target for the treatment of LUTS? Nat Rev Urol (2016) 0.76
JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy. Pharmacol Res (2014) 0.75
Palmitoylethanolamide inhibits glutamate release in rat cerebrocortical nerve terminals. Int J Mol Sci (2015) 0.75
High levels of endogenous lipid mediators (N-acylethanolamines) in women with chronic widespread pain during acute tissue trauma. Mol Pain (2016) 0.75
Peroxisome proliferator-activated receptor-gamma dependent pathway reduces the phosphorylation of dynamin-related protein 1 and ameliorates hippocampal injury induced by global ischemia in rats. J Biomed Sci (2016) 0.75
A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem (1985) 90.20
The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol (2000) 19.46
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Control of pain initiation by endogenous cannabinoids. Nature (1998) 4.73
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 4.60
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature (2002) 3.11
Regulation of the intracellular free calcium concentration in single rat dorsal root ganglion neurones in vitro. J Physiol (1990) 3.09
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain (2001) 2.59
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther (2006) 2.30
Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience (2000) 2.28
Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther (2002) 2.01
Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci (1997) 1.99
Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci (1996) 1.62
Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem (2001) 1.57
Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci (2001) 1.50
Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med (2009) 1.45
Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol (2001) 1.45
Alteration of neuropathic and visceral pain in female C57BL/6J mice lacking the PPAR-α gene. Psychopharmacology (Berl) (2012) 1.44
Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology (2009) 1.39
Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology (2001) 1.35
Protein kinase C mediates up-regulation of tetrodotoxin-resistant, persistent Na+ current in rat and mouse sensory neurones. J Physiol (2005) 1.34
Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett (2001) 1.28
Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J (2004) 1.25
Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol (2007) 1.22
Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J Biol Chem (2002) 1.22
Differential expression of membrane currents in dissociated mouse primary sensory neurons. Neuroscience (1994) 1.16
Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol (2009) 1.14
Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol (2008) 1.14
A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci (2008) 1.13
Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta (2005) 1.12
Hyperalgesic priming in the rat demonstrates marked sexual dimorphism. Pain (2003) 1.08
Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol (2001) 1.07
Chemical interactions between fibrosarcoma cancer cells and sensory neurons contribute to cancer pain. J Neurosci (2007) 1.06
Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons. J Neurosci (2004) 1.06
Bone cancer pain. Cancer (2003) 1.06
N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem J (2004) 1.05
Modulation of transient receptor potential Vanilloid 4-mediated membrane currents and synaptic transmission by protein kinase C. Mol Pain (2009) 0.99
Activation of protein kinase C in sensory neurons accelerates Ca2+ uptake into the endoplasmic reticulum. J Neurosci (2006) 0.98
Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res (2011) 0.97
Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci (2012) 0.96
β-Lactones Inhibit N-acylethanolamine Acid Amidase by S-Acylation of the Catalytic N-Terminal Cysteine. ACS Med Chem Lett (2012) 0.91
Quantitative estimation of the effects of capsaicin on the mouse primary sensory neurons. Neurosci Lett (1987) 0.85
P2X receptors in sensory neurons co-cultured with cancer cells exhibit a decrease in opioid sensitivity. Eur J Neurosci (2008) 0.81
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 5.70
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 4.60
An endocannabinoid mechanism for stress-induced analgesia. Nature (2005) 4.03
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci (2010) 2.73
A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 2.52
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther (2006) 2.30
RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol (2004) 2.12
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem (2004) 2.05
URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol (2007) 2.05
A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids (2002) 1.98
The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther (2007) 1.96
Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci (2005) 1.92
PER2 controls lipid metabolism by direct regulation of PPARγ. Cell Metab (2010) 1.91
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol (2006) 1.83
Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron (2003) 1.80
Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry (2007) 1.79
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem (2004) 1.73
Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem (2006) 1.71
The search for the palmitoylethanolamide receptor. Life Sci (2005) 1.68
Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol (2005) 1.66
Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A (2009) 1.64
A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol (2007) 1.63
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 1.55
Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 1.54
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem (2003) 1.50
A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci (2011) 1.50
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology (2005) 1.49
Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett (2008) 1.36
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther (2006) 1.31
Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology (2003) 1.30
Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A (2011) 1.29
Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther (2008) 1.29
Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology (2006) 1.28
Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc Natl Acad Sci U S A (2009) 1.25
Deficiency of lipoprotein lipase in neurons modifies the regulation of energy balance and leads to obesity. Cell Metab (2011) 1.25
Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun (2012) 1.24
Lipidomic analysis of endocannabinoid metabolism in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.23
Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol (2007) 1.22
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurobiol (2009) 1.20
Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. J Lipid Res (2007) 1.20
Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther (2007) 1.18
Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry (2011) 1.18
Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol (2008) 1.16
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci (2003) 1.16
Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One (2010) 1.15
Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol (2009) 1.14
A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci (2008) 1.13
Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther (2008) 1.12
N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids (2002) 1.11
Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med (2003) 1.11
A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. ChemMedChem (2009) 1.11
Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol (2011) 1.10
Neurotrophin activation of NFAT-dependent transcription contributes to the regulation of pro-nociceptive genes. J Neurochem (2007) 1.10
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res (2007) 1.09
Postprandial increase of oleoylethanolamide mobilization in small intestine of the Burmese python (Python molurus). Am J Physiol Regul Integr Comp Physiol (2005) 1.09
2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab (2012) 1.09
The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) (2007) 1.08
The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci (2012) 1.08
The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology (2008) 1.07
Targeted lipidomics: signaling lipids and drugs of abuse. Prostaglandins Other Lipid Mediat (2005) 1.07
Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol Pharmacol (2011) 1.07
Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry (2009) 1.06
Chemical interactions between fibrosarcoma cancer cells and sensory neurons contribute to cancer pain. J Neurosci (2007) 1.06
Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. Eur J Neurosci (2004) 1.06
Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacol Res (2012) 1.06
Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke (2002) 1.04
The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin. J Neurosci (2010) 1.04
Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). Ann Chim (2007) 1.04
Rapid pain modulation with nuclear receptor ligands. Brain Res Rev (2008) 1.03
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Sci Rep (2013) 1.02
Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology (2005) 1.02
Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology (Berl) (2008) 1.01
Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol (2009) 1.01
Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. ChemMedChem (2006) 1.01
Regulation of brain anandamide by acute administration of ethanol. Biochem J (2007) 0.99
Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain (2012) 0.99
The anandamide transport inhibitor AM404 reduces ethanol self-administration. Eur J Neurosci (2007) 0.98
Brown adipose tissue quantification in human neonates using water-fat separated MRI. PLoS One (2013) 0.97
Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. J Med Chem (2008) 0.97
Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. J Med Chem (2010) 0.97
Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur J Pharmacol (2006) 0.96
Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep (2003) 0.96
Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. Chem Commun (Camb) (2007) 0.95
Conformational effects in enzyme catalysis: reaction via a high energy conformation in fatty acid amide hydrolase. Biophys J (2006) 0.94
Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. Pharmacol Res (2004) 0.94
Lipidomic analysis of biological samples by liquid chromatography coupled to mass spectrometry. Methods Mol Biol (2009) 0.93
Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology (Berl) (2006) 0.93
Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem (2006) 0.93
Tandem mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. J Mass Spectrom (2004) 0.93
Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. ChemMedChem (2009) 0.93
Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J Neurosci (2012) 0.93
Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology (2010) 0.92
Oleylethanolamide activates Ras-Erk pathway and improves myocardial function in doxorubicin-induced heart failure. Endocrinology (2005) 0.91